Significance of Neoadjuvant S-1-Based Chemotherapy for Older Patients With Locally Advanced Gastric Cancer

Kawabata, Kota; Saito, Takuro; Kurokawa, Yukinori; Yamamoto, Kazuyoshi; Takahashi, Tsuyoshi; Tanaka, Koji; Makino, Tomoki; Nakajima, Kiyokazu; Eguchi, Hidetoshi; Doki, Yuichiro

doi:https://doi.org/10.1002/ags3.70049

Significance of Neoadjuvant S-1-Based Chemotherapy for Older Patients With Locally Advanced Gastric Cancer

Kawabata, Kota; Saito, Takuro; Kurokawa, Yukinori et al.

Annals of Gastroenterological Surgery, 2025

アクセス数:4件（2025-07-18 21:02 集計）

固定URL: https://hdl.handle.net/11094/102241

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
AnnGastroenterolSurg	pdf	なし	1.05 MB	4	2025.07.10

Creative Commons : 表示

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Significance of Neoadjuvant S-1-Based Chemotherapy for Older Patients With Locally Advanced Gastric Cancer
著者	著者名 Kawabata, Kota
	NRID 1000020646468 1000020646468 researchmap permalink tsaito19 tsaito19 Scopus Author ID 57211629912 57211629912 著者名 Saito, Takuro
	NRID 1000010470197 1000010470197 researchmap permalink krkw krkw Scopus Author ID 7202562410 7202562410 著者名 Kurokawa, Yukinori
	NRID 1000070528637 1000070528637 researchmap permalink kymamoto13 kymamoto13 Scopus Author ID 12764120500 12764120500 著者名 Yamamoto, Kazuyoshi
	NRID 1000050452389 1000050452389 ORCID 0000-0003-2397-1478 0000-0003-2397-1478 researchmap permalink mihogaoka13611 mihogaoka13611 Scopus Author ID 56182761100 56182761100 著者名 Takahashi, Tsuyoshi
	NRID 1000070621019 1000070621019 ORCID 0000-0001-5178-9388 0000-0001-5178-9388 researchmap permalink koji_tanaka koji_tanaka Scopus Author ID 55628548952 55628548952 著者名 Tanaka, Koji
	NRID 1000080528620 1000080528620 researchmap permalink _-_-_- _-_-_- Scopus Author ID 56339970700 56339970700 著者名 Makino, Tomoki
	NRID 1000030432537 1000030432537 ORCID 0000-0001-8635-7585 0000-0001-8635-7585 researchmap permalink project_engine project_engine Scopus Author ID 7404396263 7404396263 著者名 Nakajima, Kiyokazu
	NRID 1000090542118 1000090542118 researchmap permalink abcdabcdabcd abcdabcdabcd Scopus Author ID 7101627772 7101627772 著者名 Eguchi, Hidetoshi
	NRID 1000020291445 1000020291445 researchmap permalink ydoki3251 ydoki3251 Scopus Author ID 7006390687 7006390687 著者名 Doki, Yuichiro
キーワード等	gastric cancer
	neoadjuvant chemotherapy
	older patients
	preoperative DOS
	preoperative SOX
内容	Kawabata K., Saito T., Kurokawa Y., et al. Significance of Neoadjuvant S-1-Based Chemotherapy for Older Patients With Locally Advanced Gastric Cancer. Annals of Gastroenterological Surgery, (2025); https://doi.org/10.1002/ags3.70049.
抄録	Background: Neoadjuvant chemotherapy (NAC) has been extensively developed for locally advanced gastric cancer (GC). In Asia, S-1-based regimens, such as docetaxel, oxaliplatin, and S-1 (DOS) and S-1 and oxaliplatin (SOX), are expected to become the standard of care. However, the data on the significance of NAC for older patients with advanced GC remains scarce. Therefore, this study aimed to evaluate the feasibility and efficacy of NAC in older patients. Methods: We retrospectively analyzed the data from patients with cStage II–III locally advanced GC who underwent radical surgery at our institution between 2015 and 2021. This study included three groups: 56 patients with NAC and age < 75 years (NAC-Young group), 20 with NAC and age ≥ 75 years (NAC-Older group), and 46 without NAC and age ≥ 75 years (OP-Older group). Patient backgrounds, adverse events of NAC, and prognoses were compared among the groups. Results: Compared with the NAC-Young group, the NAC-Older group was more likely to receive the SOX regimen and reduced initial doses, but there was no significant difference in the incidence of adverse events of NAC and prognosis. Compared to the OP-Older group, overall survival and cancer-specific survival tended to be better in the NAC-Older group at cStage III. Moreover, for patients with cStage III and ECOG-PS 0, cancer-specific survival was significantly better in the NAC-Older group compared to the OP-Older group (p = 0.030). Conclusions: NAC with S-1-based regimens is a feasible and effective treatment option for older patients with GC with advanced-stage disease and good overall condition.
出版者	John Wiley and Sons Inc
収録物名	Annals of Gastroenterological Surgery
刊行年月	2025-05-31
言語	英語
ハンドルURL	https://hdl.handle.net/11094/102241
eISSN	24750328
関連情報 (isIdenticalTo)	DOI (出版社版) https://doi.org/10.1002/ags3.70049
アクセス権	open access
権利情報	This article is licensed under a Creative Commons Attribution 4.0 International License.
出版タイプ	Version of Record
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCMI資源タイプ	text
DCTERMS.bibliographicCitation	Annals of Gastroenterological Surgery. 2025
DC.title	Significance of Neoadjuvant S-1-Based Chemotherapy for Older Patients With Locally Advanced Gastric Cancer
DC.creator	Kawabata, Kota
	Saito, Takuro
	Kurokawa, Yukinori
	Yamamoto, Kazuyoshi
	Takahashi, Tsuyoshi
	Tanaka, Koji
	Makino, Tomoki
	Nakajima, Kiyokazu
	Eguchi, Hidetoshi
	Doki, Yuichiro
DC.publisher	John Wiley and Sons Inc
DC.language' scheme='DCTERMS.RFC1766	英語
DC.type' scheme='DCTERMS.DCMIType	text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2025-05-31
DC.identifier	https://doi.org/10.1002/ags3.70049
DC.subject	gastric cancer
	neoadjuvant chemotherapy
	older patients
	preoperative DOS
	preoperative SOX
DC.description	Kawabata K., Saito T., Kurokawa Y., et al. Significance of Neoadjuvant S-1-Based Chemotherapy for Older Patients With Locally Advanced Gastric Cancer. Annals of Gastroenterological Surgery, (2025); https://doi.org/10.1002/ags3.70049.
DCTERMS.abstract	Background: Neoadjuvant chemotherapy (NAC) has been extensively developed for locally advanced gastric cancer (GC). In Asia, S-1-based regimens, such as docetaxel, oxaliplatin, and S-1 (DOS) and S-1 and oxaliplatin (SOX), are expected to become the standard of care. However, the data on the significance of NAC for older patients with advanced GC remains scarce. Therefore, this study aimed to evaluate the feasibility and efficacy of NAC in older patients. Methods: We retrospectively analyzed the data from patients with cStage II–III locally advanced GC who underwent radical surgery at our institution between 2015 and 2021. This study included three groups: 56 patients with NAC and age < 75 years (NAC-Young group), 20 with NAC and age ≥ 75 years (NAC-Older group), and 46 without NAC and age ≥ 75 years (OP-Older group). Patient backgrounds, adverse events of NAC, and prognoses were compared among the groups. Results: Compared with the NAC-Young group, the NAC-Older group was more likely to receive the SOX regimen and reduced initial doses, but there was no significant difference in the incidence of adverse events of NAC and prognosis. Compared to the OP-Older group, overall survival and cancer-specific survival tended to be better in the NAC-Older group at cStage III. Moreover, for patients with cStage III and ECOG-PS 0, cancer-specific survival was significantly better in the NAC-Older group compared to the OP-Older group (p = 0.030). Conclusions: NAC with S-1-based regimens is a feasible and effective treatment option for older patients with GC with advanced-stage disease and good overall condition.
DC.rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
DC.format	102241
citation_title	Significance of Neoadjuvant S-1-Based Chemotherapy for Older Patients With Locally Advanced Gastric Cancer
citation_author	Kawabata, Kota
	Saito, Takuro
	Kurokawa, Yukinori
	Yamamoto, Kazuyoshi
	Takahashi, Tsuyoshi
	Tanaka, Koji
	Makino, Tomoki
	Nakajima, Kiyokazu
	Eguchi, Hidetoshi
	Doki, Yuichiro
citation_publisher	John Wiley and Sons Inc
citation_language	英語
citation_date	2025-05-31
citation_journal_title	Annals of Gastroenterological Surgery
citation_doi	https://doi.org/10.1002/ags3.70049
citation_public_url	https://hdl.handle.net/11094/102241

Significance of Neoadjuvant S-1-Based Chemotherapy for Older Patients With Locally Advanced Gastric Cancer

閲覧可能ファイル

論文情報

論文詳細を表示